Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions

Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment

The Swiss pharmaceutical firm Novartis has ditched plans for a large clinical trial in the UK, in a further blow to the government’s efforts to make Britain an attractive place for research and investment after Brexit.

The company decided to scrap the Orion-17 trial of its cholesterol-lowering drug Leqvio, involving 40,000 patients in partnership with NHS England.

Continue reading...

Senate Democrats blast former Trump attorney for ‘selling access’ to White House

Michael Cohen's relationship with the Swiss drug company Novartis was more extensive than the company previously disclosed, as shown in newly uncovered emails exchanged by President Donald Trump 's former lawyer and the company's former top executive. Add Donald Trump as an interest to stay up to date on the latest Donald Trump news, video, and analysis from ABC News.

Trump tax cuts could mean more Novartis investment in U.S

Donald Trump's plans to cut U.S. corporate tax rates could trigger increased investment in the United States by Novartis, its chief executive told Reuters, despite the president-elect's recent harsh words on drug prices. "When we build a new manufacturing site we think about the tax rate, we think about the economy of the country, we think about jobs, so a booming U.S. economy would make the U.S. more attractive for investment," Joe Jimenez said on Wednesday.